Synthetic Cannabinoid Pharmacology and Toxicology

Synthetic cannabinoids comprise a structurally diverse class of compounds engineered to bind cannabinoid receptors with often greater affinity and efficacy than Δ9-tetrahydrocannabinol, the principal psychoactive constituent of cannabis. Initially developed as pharmacological probes to elucidate endocannabinoid signalling, many have since emerged as potent new psychoactive substances. Their variable chemical scaffolds—indoles, indazoles, benzimidazoles and related heterocycles—allow rapid circumvention of legal controls, giving rise to an ever-evolving market. Pharmacologically, these agents frequently act as full agonists at the CB1 receptor, leading to more intense and unpredictable central nervous system effects, including psychomotor agitation, memory impairment and disrupted synaptic plasticity. Metabolic clearance often involves extensive phase I oxidative transformations and phase II conjugations, yielding active metabolites that may retain receptor affinity and contribute to prolonged or delayed toxicity. Clinically, synthetic cannabinoids have been implicated in severe cardiovascular, neurological and psychiatric adverse events, and fatal overdoses have been reported worldwide. The global proliferation of these compounds presents significant challenges for forensic detection, toxicological screening and public health responses.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Synthetic Cannabinoid Pharmacology and Toxicology publication trend

The graph below shows the total number of articles in synthetic cannabinoid pharmacology and toxicology across all publications each year (not limited to Nature Index journals).

Technical terms

CB1 receptor: A G-protein-coupled receptor in the central nervous system that mediates most of the psychoactive effects of cannabinoids.

Endocannabinoid system: A biological network comprising endogenous ligands (e.g. anandamide), receptors (CB1, CB2) and metabolic enzymes that modulates neural and immune functions.

Synthetic cannabinoid receptor agonist (SCRA): A man-made compound that activates cannabinoid receptors, often with higher potency than natural cannabinoids.

Pharmacokinetics: The study of how a compound is absorbed, distributed, metabolised and excreted by the body.

Metabolite: A product of the chemical alteration of a parent drug by enzymatic processes, some of which may retain pharmacological activity.

Δ9-Tetrahydrocannabinol (THC): The principal psychoactive constituent of cannabis, acting as a partial agonist at CB1 receptors.

References

1. Beyond THC: The New Generation of Cannabinoid Designer Drugs. Frontiers in Behavioral Neuroscience (2011).
2. Pharmacological evaluation of new constituents of “Spice”: synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds. Forensic Toxicology (2018).
3. Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity. PLOS ONE (2011).
4. Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective. Frontiers in Public Health (2018).
5. Intermolecular through‐space charge transfer enabled by bicomponent assembly for ultrasensitive detection of synthetic cannabinoid JWH‐018. Aggregate (2023).
6. Cognitive dysfunction and impaired neuroplasticity following repeated exposure to the synthetic cannabinoid JWH‐018 in male mice. British Journal of Pharmacology (2023).
7. New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites. Frontiers in Chemistry (2019).